Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay
Marlyn J. Mayo(Southwestern Medical Center), William Rosenberg(University of Southampton), Velimir A. Luketic(University of Padua), Guadalupe García–Tsao(Connecticut Health Foundation), Robert Butsch(The University of Texas Southwestern Medical Center), Adrian M. Di Bisceglie(Saint Louis University), Julie Parkes(University of Southampton), James L. Boyer(Celldex Therapeutics (United States)), Marion G. Peters(Northwestern University), Thomas Boyer(Centre Hospitalier Universitaire Amiens-Picardie), David S. Barnes, Sandra Saldana(Loma Linda University), Beverley Adams‐Huet(Southwestern Medical Center), A. Brian West(Yale University), Burton Combes(The University of Texas Southwestern Medical Center), A. Scott Mills(Virginia Commonwealth University Medical Center), Enrique Martínez(Atlanta Gastroenterology Associates), Melissa J. Contos(Virginia Commonwealth University Medical Center), Rodney S. Markin(University of Nebraska Medical Center), Raphael Rubin(Thomas Jefferson University), Donald E. Wheeler(University of South Florida), Yonas Getachew(The University of Texas Southwestern Medical Center), Nathan M. Bass(University of California, San Francisco), John R. Lake(University of Minnesota)
Cited by 199
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus Infection
|Science|2004|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k